Your browser doesn't support javascript.
loading
Effect of proprotein convertase subtilisin/kexin type 9 inhibition on cancer events: A pooled, post hoc, competing risk analysis of alirocumab clinical trials.
Mohammadi, Kusha A; Brackin, Taylor; Schwartz, Gregory G; Steg, Philippe Gabriel; Szarek, Michael; Manvelian, Garen; Pordy, Robert; Fazio, Sergio; Geba, Gregory P.
Affiliation
  • Mohammadi KA; Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.
  • Brackin T; Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.
  • Schwartz GG; University of Colorado School of Medicine, Aurora, Colorado, USA.
  • Steg PG; Université Paris-Cité, Paris, France.
  • Szarek M; FACT (French Alliance for Cardiovascular Trials) INSERM U1148, Paris, France.
  • Manvelian G; Assistance Publique-Hôpitaux de Paris, Hôpital Bichat, Paris, France.
  • Pordy R; State University of New York, Downstate School of Public Health, Brooklyn, New York, USA.
  • Fazio S; CPC Clinical Research and Division of Cardiology, University of Colorado School of Medicine, Aurora, Colorado, USA.
  • Geba GP; Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.
Cancer Med ; 12(16): 16859-16868, 2023 08.
Article in En | MEDLINE | ID: mdl-37458138
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: PCSK9 Inhibitors / Antibodies, Monoclonal / Neoplasms Type of study: Clinical_trials / Etiology_studies / Risk_factors_studies Limits: Humans Language: En Journal: Cancer Med Year: 2023 Document type: Article Affiliation country: Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: PCSK9 Inhibitors / Antibodies, Monoclonal / Neoplasms Type of study: Clinical_trials / Etiology_studies / Risk_factors_studies Limits: Humans Language: En Journal: Cancer Med Year: 2023 Document type: Article Affiliation country: Country of publication: